Prosecution Insights
Last updated: November 20, 2026
Application No. 17/632,840

LEAFLET COAPTATION-ASSISTANCE DEVICES

Final Rejection §102§103
Filed
Feb 04, 2022
Priority
Aug 08, 2019 — provisional 62/884,404 +1 more
Examiner
BLASS, PARIS MARIE
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Mtex Cardio AG
OA Round
2 (Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
21 granted / 36 resolved
-11.7% vs TC avg
Strong +44% interview lift
Without
With
+43.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
32 currently pending
Career history
86
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
49.6%
+9.6% vs TC avg
§102
32.2%
-7.8% vs TC avg
§112
17.1%
-22.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 36 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Response to Amendment The amendment filed 02/18/2026 has been entered. Claims 1, 2, 4-7, 10-13, 15, 20-21, 24, and 26 and 102-105 remain pending in the application. Claim 106 has been cancelled. Claims 102-105 remain withdrawn from consideration. New claim 107 has been added. Response to Arguments Applicant's arguments filed 02/18/20226 have been fully considered but they are not persuasive. Regarding the argument that Khairkhahan no longer discloses amended claim 1, the Examiner respectfully disagrees. The newly interpreted “upper” and “lower” surfaces contact the atrial sides of both leaflets, and the surfaces 292 and 294 are disclosed to comprise a “covering” which can be considered a sheet. Regarding the argument that Khairkhahan does not disclose amended claim 7, the Examiner respectfully disagrees. The limitation “ventrical apical area” is being given it’s broadest reasonable interpretation, in that area is being interpreted to mean “the amount of space inside a shape, surface, region, room, etc.” (see Merriam Webster Online definition 4). The ventricle side of the leaflets can be considered to be apart of the “ventrical apical area,” as it is within an area around the apex of the heart on the ventricle side of the leaflets. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2, 4, 6-7, 10-13, 15, 20-21, 24, 26, and 107 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US 20150119981 A1 (hereafter --Khairkhahan--). Regarding Claim 1, Khairkhahan discloses a leaflet coaptation-assist device (280) for promoting valve coaptation of leaflets of an atrioventricular valve of a heart of a patient (see paragraph [0084]), the leaflet coaptation-assist device comprising: a sheet having a lower surface (292) that provides a coaptation-assist surface (290) (see annotated coaptation-assist surface 290 in Figure 13 below, see also paragraph [0086] denoting that surfaces 292 and 294 provide a coaptation surface, see also paragraph [0088] can comprise of a “covering” which can be considered a “sheet”); and one or more tissue anchors (296) (see annotated tissue anchor 296 in Figure 13 below, see also paragraph [0090]), which are configured to anchor the leaflet coaptation- assist device in place within the heart of the patient (see paragraphs [0090] and [0091]), such that the coaptation-assist surface provided by the lower surface (292) (see paragraph [0086] denoting that surfaces 292 and 294 provide a coaptation surface, see also annotated lower surface in Figure 13 below, in which the lower surface includes both 292 and 294 and therefore contacts the atrial side of both leaflets) of the sheet is located at or below a leaflet hinge line and contacts an atrial side of the leaflets during ventricular systole (see paragraph [0086], see also Figure 14D below), thereby enhancing leaflet coaptation, the leaflets selected from the group consisting of: native leaflets and prosthetic leaflets (see paragraph [0086]), wherein the one or more tissue anchors comprise a non-tissue-piercing anchor (see paragraph [0090] denoting that clips, helixes or harpoons are options for anchors, see also tissue anchor 296 in Figures 13 and 14D below), which comprises one or more ventricular loops (see paragraphs [0085] and [0090] denoting that helixes are an option, which have loops, see also annotated loops in Figure 13 below), which are configured to couple the leaflet coaptation-assist device to a ventricular wall by radial force and friction (see paragraphs [0090] and [0091]). PNG media_image1.png 563 951 media_image1.png Greyscale PNG media_image2.png 297 605 media_image2.png Greyscale Regarding Claim 2, Khairkhahan discloses the leaflet coaptation-assist device according to claim 1, wherein the one or more ventricular loops are configured to contact one or more of the atrioventricular leaflets at the commissural level and clip the one or more leaflets within the one or more ventricular loops to stabilize anchoring of the leaflet coaptation-assist device (see paragraphs [0090] and [0091]). Regarding Claim 4, Khairkhahan discloses the leaflet coaptation-assist device according to claim 7, wherein the non- tissue-piercing anchor comprises two or more ventricular loops (see paragraph [0090] denoting that the anchor can comprise of a plurality of helixes, in which a plurality of helixes have at least two loops, see also annotated loops in Figure 13 below). Regarding Claim 6, Khairkhahan discloses the leaflet coaptation-assist device according to claim 4, wherein the two or more ventricular loops do not cross or touch one another (see annotated loops in Figure 13 above). Regarding Claim 7, Khairkhahan discloses a leaflet coaptation-assist device (280) for promoting valve coaptation of leaflets of an atrioventricular valve of a heart of a patient (see paragraph [0084]), the leaflet coaptation-assist device comprising: a coaptation-assist surface (see annotated coaptation-assist surface 290 including surfaces 292 and 294 in Figure 13 above, see also paragraph [0086] denoting that surfaces 292 and 294 provide a coaptation surface, see also paragraph [0088] can comprise of a “covering” which can be considered a “sheet”); and one or more tissue anchors (296) (see annotated tissue anchor 296 in Figure 13 above, see also paragraph [0090]), which are configured to anchor the leaflet coaptation- assist device in place within the heart of the patient (see paragraphs [0090] and [0091]), such that the coaptation-assist surface is located at or below a leaflet hinge line and contacts an atrial side of the leaflets during ventricular systole (see paragraph [0086] denoting that surfaces 292 and 294 provide a coaptation surface, see also annotated lower surface in Figure 13 below, in which the lower surface includes both 292 and 294 and therefore contacts the atrial side of both leaflets, see also paragraph [0086], see also Figure 14D above), thereby enhancing leaflet coaptation, the leaflets selected from the group consisting of: native leaflets and prosthetic leaflets (see paragraph [0086]), wherein the one or more tissue anchors comprise a non-tissue-piercing anchor (see paragraph [0090] denoting that clips, helixes or harpoons are options for anchors, see also tissue anchor 296 in Figures 13 and 14D above), which comprises one or more ventricular loops (see paragraphs [0085] and [0090] denoting that helixes are an option, which have loops, see also annotated loops in Figure 13 above), which are configured to couple the leaflet coaptation-assist device to a ventricular wall by radial force and friction (see paragraphs [0090] and [0091]), wherein the one or more ventricular loops are configured to reach to a ventricular apical area (see paragraph [0090], see also annotated loops in Figure 14D above in which they are in contact with the ventricular side). Regarding Claim 10, Khairkhahan discloses the leaflet coaptation-assist device according to claim 1, wherein the one or more tissue anchors are configured to anchor the leaflet coaptation-assist device in place within the heart of the patient (see paragraphs [0090] and [0091]), such that the coaptation-assist surface is located at the leaflet hinge line and contacts the atrial side of the leaflets during ventricular systole (see Figure 14D above), The limitation “thereby blocking motion of the leaflets into an atrium and preventing leaflet prolapse” is treated as functional language, that is given limited patentable weight. The prior art is not required to disclose this function, but merely have the capability of performing the recited function. Due to the leaflet coaptation-assist device being located on the atrial side of the valve at the leaflet hinge line (see Figure 14D above), the device is able to block motion of the leaflets into the atrium, therefore preventing leaflet prolapse, as the device itself is disclosed to have the purpose of preventing valve regurgitation (see Abstract). Regarding Claim 11, Khairkhahan discloses the leaflet coaptation-assist device according to claim 1, wherein the one or more tissue anchors are configured to anchor the leaflet coaptation-assist device in place within the heart of the patient (see paragraphs [0090] and [0091]), such that the coaptation-assist surface is located below the leaflet hinge line such that the leaflets partially coapt with the coaptation-assist surface during ventricular systole (see Figure 13 above, see also paragraph [0086]). Regarding Claim 12, Khairkhahan discloses the leaflet coaptation-assist device according to claim 7, wherein the leaflet coaptation-assist device comprises a sheet having a lower surface that provides the coaptation-assist surface (see annotated sheet and lower surface in Figure 13 above, see also paragraphs [0086]-[0088] denoting that surfaces 292 and 294 can comprise of a covering). Regarding Claim 13, Khairkhahan discloses the leaflet coaptation-assist device according to claim 1, wherein the sheet has four sides (see annotated four sides in Figure 13 above). Regarding Claim 15, Khairkhahan discloses the leaflet coaptation-assist device according to claim 1, wherein the sheet is shaped so as to define three spokes extending radially outward from a central hub region (see annotated spokes and central hub in Figure 13 above). Regarding Claim 20, Khairkhahan discloses the leaflet coaptation-assist device according to claim 1, wherein the sheet has two longer sides and two shorter sides (see annotated longer sides (first and second) and shorter sides (third and fourth) in Figure 13 above), and the shorter sides include respective stiffened portions (the shorter “sides” are stiffened as they directly have the nitinol wire under them, making them more stiff than the upper and lower surfaces, or other two sides (first and second)). Regarding Claim 21, Khairkhahan discloses the leaflet coaptation-assist device according to claim 7, wherein the leaflet coaptation-assist device comprises a thick structure having a lower surface that provides the coaptation-assist surface (see annotated thick structure and lower surface in Figure 13 above, see also paragraphs [0086]-[0088] denoting that surfaces 292 and 294 can comprise of a covering, which can be considered a thick structure). Regarding Claim 24, Khairkhahan discloses the leaflet coaptation-assist device according to claim 21, wherein the thick structure is curved on a ventricular side thereof (see annotated sheet and lower surface in Figure 14D above, see also paragraphs [0086]-[0088] denoting that surfaces 292 and 294 can comprise of a covering, see bottom side of anchor being curved on the ventricular side in Figures 13 and 14D above). Regarding Claim 26, Khairkhahan discloses the leaflet coaptation-assist device according to claim 24, wherein the thick structure is flat on an atrial side thereof (see annotated flat portion in Figures 13 and 14 above). Regarding Claim 107, Khairkhahan discloses the leaflet coaptation-assist device according to claim 1, wherein the one or more ventricular loops are configured to reach to a ventricular apical area (see paragraph [0090], see also annotated loops in Figure 14D above in which they are in contact with the ventricular side). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim 5 is rejected under 35 U.S.C. 103 as being unpatentable over US 20150119981 A1 (hereafter --Khairkhahan--). Regarding Claim 5, Khairkhahan discloses the leaflet coaptation-assist device according to claim 4. This embodiment of Khairkhahan fails to disclose wherein the two or more ventricular loops cross one another. Another embodiment of Khairkhahan teaches wherein the two or more ventricular loops cross one another (see annotated ventricular loops of tissue anchor 94 in Figures 5D and 6D below). PNG media_image3.png 357 821 media_image3.png Greyscale The Instant Application does not disclose having the two or more ventricular loops crossing one another solves any problem or is for any particular purpose, nor does it place criticality on the limitation. It appears that Khairkhahan’s outer frame would perform equally and function as intended with the two or more ventricular loops crossing one another, as the tissue anchor would still secure the leaflet coaptation-assist device to the leaflet and would sit on the ventricular side, regardless of specific shape. Finally, a person having ordinary skill in the art before the effective filing date would have a reasonable expectation of success in making such a modification, since Khairkhahan discloses that this anchor resists movement of the coaptation assistance device 80, causing stability, and can do so without penetrating the myocardium as taught by Khairkhahan (see paragraph [0050]), as well as Khairkhahan discloses that combinations or subcombinations of the specific features and aspects of the embodiments disclosed above may be made and still fall within one or more of the inventions (see paragraph [0122]). Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date to make the two or more ventricular loops cross one another as taught by Khairkhahan in the embodiment above, as an obvious matter of design choice within the skill of the art. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PARIS MARIE BLASS whose telephone number is (703)756-5375. The examiner can normally be reached Monday - Thursday 9 a.m. - 7 p.m. ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PARIS MARIE BLASS/Examiner, Art Unit 3774 /SARAH W ALEMAN/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Feb 04, 2022
Application Filed
Aug 21, 2025
Non-Final Rejection mailed — §102, §103
Feb 18, 2026
Response Filed
May 11, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788562
ARTICULATED PROSTHESIS FOR A TRICUSPID OR MITRAL VALVE AND RELATED CATCHING DEVICE
2y 6m to grant Granted Nov 10, 2026
Patent 12702570
IMPACTION CRADLE
4y 3m to grant Granted Aug 11, 2026
Patent 12690959
ARTIFICIAL BLADDER SYSTEM
3y 9m to grant Granted Jul 28, 2026
Patent 12653672
PERICARDIAL ANCHORING SYSTEM
4y 1m to grant Granted Jun 16, 2026
Patent 12653671
DELIVERY SYSTEM HAVING A SPLIT DISTAL TIP FOR IMPROVED POSITIONING OF A TRANSCATHETER HEART VALVE
3y 7m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+43.8%)
3y 8m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 36 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month